These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

509 related articles for article (PubMed ID: 29074501)

  • 1. Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial.
    Bartlett NL; Costello BA; LaPlant BR; Ansell SM; Kuruvilla JG; Reeder CB; Thye LS; Anderson DM; Krysiak K; Ramirez C; Qi J; Siegel BA; Griffith M; Griffith OL; Gomez F; Fehniger TA
    Blood; 2018 Jan; 131(2):182-190. PubMed ID: 29074501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Phase II Study Assessing Long-term Response to Ibrutinib Monotherapy in Recurrent or Refractory CNS Lymphoma.
    Grommes C; Nandakumar S; Schaff LR; Gavrilovic I; Kaley TJ; Nolan CP; Stone J; Thomas AA; Tang SS; Wolfe J; Bozza A; Wongchai V; Hyde A; Barrett E; Lynch EA; Madzsar JT; Lin A; Piotrowski AF; Pentsova E; Francis JH; Hatzoglou V; Schultz N; Reiner AS; Panageas KS; DeAngelis LM; Mellinghoff IK
    Clin Cancer Res; 2024 Sep; 30(18):4005-4015. PubMed ID: 38995739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma.
    Grommes C; Pastore A; Palaskas N; Tang SS; Campos C; Schartz D; Codega P; Nichol D; Clark O; Hsieh WY; Rohle D; Rosenblum M; Viale A; Tabar VS; Brennan CW; Gavrilovic IT; Kaley TJ; Nolan CP; Omuro A; Pentsova E; Thomas AA; Tsyvkin E; Noy A; Palomba ML; Hamlin P; Sauter CS; Moskowitz CH; Wolfe J; Dogan A; Won M; Glass J; Peak S; Lallana EC; Hatzoglou V; Reiner AS; Gutin PH; Huse JT; Panageas KS; Graeber TG; Schultz N; DeAngelis LM; Mellinghoff IK
    Cancer Discov; 2017 Sep; 7(9):1018-1029. PubMed ID: 28619981
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma.
    Grommes C; Tang SS; Wolfe J; Kaley TJ; Daras M; Pentsova EI; Piotrowski AF; Stone J; Lin A; Nolan CP; Manne M; Codega P; Campos C; Viale A; Thomas AA; Berger MF; Hatzoglou V; Reiner AS; Panageas KS; DeAngelis LM; Mellinghoff IK
    Blood; 2019 Jan; 133(5):436-445. PubMed ID: 30567753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN Study.
    Gopal AK; Schuster SJ; Fowler NH; Trotman J; Hess G; Hou JZ; Yacoub A; Lill M; Martin P; Vitolo U; Spencer A; Radford J; Jurczak W; Morton J; Caballero D; Deshpande S; Gartenberg GJ; Wang SS; Damle RN; Schaffer M; Balasubramanian S; Vermeulen J; Cheson BD; Salles G
    J Clin Oncol; 2018 Aug; 36(23):2405-2412. PubMed ID: 29851546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial.
    Jones JA; Mato AR; Wierda WG; Davids MS; Choi M; Cheson BD; Furman RR; Lamanna N; Barr PM; Zhou L; Chyla B; Salem AH; Verdugo M; Humerickhouse RA; Potluri J; Coutre S; Woyach J; Byrd JC
    Lancet Oncol; 2018 Jan; 19(1):65-75. PubMed ID: 29246803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutational profile in previously treated patients with chronic lymphocytic leukemia progression on acalabrutinib or ibrutinib.
    Woyach JA; Jones D; Jurczak W; Robak T; Illés Á; Kater AP; Ghia P; Byrd JC; Seymour JF; Long S; Mohamed N; Benrashid S; Lai TH; De Jesus G; Lai R; de Bruin G; Rule S; Munugalavadla V
    Blood; 2024 Sep; 144(10):1061-1068. PubMed ID: 38754046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.
    Advani RH; Buggy JJ; Sharman JP; Smith SM; Boyd TE; Grant B; Kolibaba KS; Furman RR; Rodriguez S; Chang BY; Sukbuntherng J; Izumi R; Hamdy A; Hedrick E; Fowler NH
    J Clin Oncol; 2013 Jan; 31(1):88-94. PubMed ID: 23045577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study.
    Xu W; Yang S; Zhou K; Pan L; Li Z; Zhou J; Gao S; Zhou D; Hu J; Feng R; Huang H; Ji M; Guo H; Huang J; Novotny W; Feng S; Li J
    J Hematol Oncol; 2020 May; 13(1):48. PubMed ID: 32393328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of a genetic signature enriching for response to ibrutinib in relapsed/refractory follicular lymphoma in the DAWN phase 2 trial.
    Balasubramanian S; Hodkinson B; Schuster SJ; Fowler NH; Trotman J; Hess G; Cheson BD; Schaffer M; Sun S; Deshpande S; Vermeulen J; Salles G; Gopal AK
    Cancer Med; 2022 Jan; 11(1):61-73. PubMed ID: 34791836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of ibrutinib in Japanese patients with relapsed or refractory mantle cell lymphoma.
    Maruyama D; Nagai H; Fukuhara N; Kitano T; Ishikawa T; Shibayama H; Choi I; Hatake K; Uchida T; Nishikori M; Kinoshita T; Matsuno Y; Nishikawa T; Takahara S; Tobinai K
    Cancer Sci; 2016 Dec; 107(12):1785-1790. PubMed ID: 27616553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of 2 Clinical Trials.
    O'Brien SM; Jaglowski S; Byrd JC; Bannerji R; Blum KA; Fox CP; Furman RR; Hillmen P; Kipps TJ; Montillo M; Sharman J; Suzuki S; James DF; Chu AD; Coutre SE
    JAMA Oncol; 2018 May; 4(5):712-716. PubMed ID: 29470582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group.
    Winqvist M; Asklid A; Andersson PO; Karlsson K; Karlsson C; Lauri B; Lundin J; Mattsson M; Norin S; Sandstedt A; Hansson L; Österborg A
    Haematologica; 2016 Dec; 101(12):1573-1580. PubMed ID: 27198718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.
    Wang ML; Rule S; Martin P; Goy A; Auer R; Kahl BS; Jurczak W; Advani RH; Romaguera JE; Williams ME; Barrientos JC; Chmielowska E; Radford J; Stilgenbauer S; Dreyling M; Jedrzejczak WW; Johnson P; Spurgeon SE; Li L; Zhang L; Newberry K; Ou Z; Cheng N; Fang B; McGreivy J; Clow F; Buggy JJ; Chang BY; Beaupre DM; Kunkel LA; Blum KA
    N Engl J Med; 2013 Aug; 369(6):507-16. PubMed ID: 23782157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study.
    Byrd JC; Furman RR; Coutre SE; Flinn IW; Burger JA; Blum K; Sharman JP; Wierda W; Zhao W; Heerema NA; Luan Y; Liu EA; Dean JP; O'Brien S
    Clin Cancer Res; 2020 Aug; 26(15):3918-3927. PubMed ID: 32209572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes.
    Cheah CY; Chihara D; Romaguera JE; Fowler NH; Seymour JF; Hagemeister FB; Champlin RE; Wang ML
    Ann Oncol; 2015 Jun; 26(6):1175-1179. PubMed ID: 25712454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma.
    Noy A; de Vos S; Thieblemont C; Martin P; Flowers CR; Morschhauser F; Collins GP; Ma S; Coleman M; Peles S; Smith S; Barrientos JC; Smith A; Munneke B; Dimery I; Beaupre DM; Chen R
    Blood; 2017 Apr; 129(16):2224-2232. PubMed ID: 28167659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia.
    Chen LS; Bose P; Cruz ND; Jiang Y; Wu Q; Thompson PA; Feng S; Kroll MH; Qiao W; Huang X; Jain N; Wierda WG; Keating MJ; Gandhi V
    Blood; 2018 Nov; 132(21):2249-2259. PubMed ID: 30254130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Screening and monitoring of the BTK
    Bödör C; Kotmayer L; László T; Takács F; Barna G; Kiss R; Sebestyén E; Nagy T; Hegyi LL; Mikala G; Fekete S; Farkas P; Balogh A; Masszi T; Demeter J; Weisinger J; Alizadeh H; Kajtár B; Kohl Z; Szász R; Gergely L; Gurbity Pálfi T; Sulák A; Kollár B; Egyed M; Plander M; Rejtő L; Szerafin L; Ilonczai P; Tamáska P; Pettendi P; Lévai D; Schneider T; Sebestyén A; Csermely P; Matolcsy A; Mátrai Z; Alpár D
    Br J Haematol; 2021 Jul; 194(2):355-364. PubMed ID: 34019713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103.
    Ujjani CS; Jung SH; Pitcher B; Martin P; Park SI; Blum KA; Smith SM; Czuczman M; Davids MS; Levine E; Lewis LD; Smith SE; Bartlett NL; Leonard JP; Cheson BD
    Blood; 2016 Nov; 128(21):2510-2516. PubMed ID: 27697771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.